A 28-Day Study Evaluating the Safety of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet (SCH 39641/MK-3641) Treatment in Ragweed Allergic Adults (Phase 3, Protocol No.P05751).
Phase of Trial: Phase III
Latest Information Update: 07 Mar 2017
At a glance
- Drugs Short ragweed pollen allergen extract (Ragwitek) (Primary)
- Indications Rhinoconjunctivitis
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 24 Apr 2012 Actual patient number (914) added as reported by ClinicalTrials.gov.
- 24 Apr 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
- 24 Apr 2012 Actual initiation date changed from Oct 2011 to Nov 2011 as reported by ClinicalTrials.gov.